Environment
Environment
The case for action on climate change is clear. We’re taking positive steps to reduce our carbon footprint.
In 2023, the Intergovernmental Panel on Climate Change (IPCC) reiterated the need for urgent action to avert the most severe impacts of climate change [1]. The World Health Organisation (WHO) has identified climate change as the single biggest threat to human health[2]. Whether it’s heightened exposure to a longer, more severe allergy season or the impact of increased emissions associated with air pollution and climate change on breathing, people’s everyday health is already being directly and indirectly impacted by climate change. The impact is only set to intensify unless urgent action is taken.
We’re committed to tackling carbon emissions and have set emissions reduction targets aligned to the Intergovernmental Panel on Climate Change (IPCC) pathway to 1.5º C. We are also a signatory of The Climate Pledge and we have submitted our Scope 1, 2 and 3 goals to the Science Based Targets initiative (SBTi) for validation and have registered our commitment to Net Zero.
Using 2020 as our baseline, we aim to:
We've been making significant progress in reducing our net Scope 1 and 2 carbon emissions. This has been achieved by switching to 100% renewable electricity across all our sites which we directly control, as well as through the concerted action we’ve taken to decarbonise our manufacturing operations and drive energy efficiency. Our Scope 1 and 2 programme is focused on absolute reduction of 95% of emissions from our operations, driven primarily by conversion to renewable energy sources.
Across Scope 3 carbon emissions, over half of our cradle-to-grave carbon emissions are driven by the ingredients, packaging, and services we buy and use to make our products. Key contributors to our carbon emissions from purchased goods and services include certain packaging materials and active pharmaceutical ingredients in our products.
We will focus on systematically reducing our carbon emissions by:
We launched a long-term Power Purchase Agreement (PPA) at our facility in Oak Hill, New York, which manufactures oral health products including Sensodyne and Pronamel for the North American market. We’re partnering with Ameresco Solar Energy Solutions to supply Oak Hill with 70% of its electricity from a dedicated off-site solar park.
Our Suzhou site in China is our first carbon neutral manufacturing site, meaning it has achieved net zero Scope 1 and 2 carbon emissions through carbon reduction, renewable electricity and carbon offsetting. It has been certified by Bureau Veritas Certification Beijing Co., Ltd. in accordance with the PAS 2060 standard.
We work with Forum for the Future and industry peers as a co-founding partner of the Climate and Health Coalition to highlight the human health impacts of climate change and mobilise action to deliver benefits for both climate and health.
Through the creation of The Clean Breathing Institute, we support pharmacists to give trusted advice to their patients on how to mitigate the impact of air pollution on respiratory health.
[1] AR6 Synthesis Report: Climate Change 2023 — IPCC
[2] Climate change and health (who.int)
[3] Our goal to reduce net Scope 1 and 2 carbon emissions by 100% by 2030 is underpinned by a 95% absolute reduction target. The 2020 baseline year reporting period = 1 January 2020 to 31 December 2020. Although the 2020 baseline was calculated prior to the demerger, it includes only the sites which became Haleon sites following the demerger from GSK.
[4] Our Net Zero and Scope 3 carbon emissions targets span all carbon emission categories from source to sale (excluding GHG-protocol categories 6, 7, 10-15). It covers mandatory Scope 3 upstream and downstream emissions. It excludes indirect consumers use-phase emissions, such as emissions associated with water used with our products. 2020 baseline year reporting period = 1 January 2020 to 31 December 2020.
[5] Reporting period = 1 December 2021 to 30 November 2022.
Related
